| Active substance | autologous anti-CD19 CD3+ cells (CAR+ viable T cells) |
| Holder | Gilead Sciences Belgium bv |
| Status | closed |
| Indication | treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update |
30/11/2022 |